Scientists at UC Santa Barbara, in cooperation with scientists in the pharmaceutical industry, have discovered the mechanism by which this drug kills cancer cells. The team has isolated the drug's action in the test tube as well as in cancer cells.
The results are reported in two studies published as the cover story of the October issue of Molecular Cancer Therapeutics, authored by a team of UCSB researchers. The articles feature work performed in the laboratories of Mary Ann Jordan and Leslie Wilson, professors in UCSB's Department of Cellular, Molecular and Developmental Biology.
"This anticancer drug, called maytansine, when linked to a tumor-targeting antibody, shows promising early results in clinical trials on patients with metastatic breast cancer," said Jordan. "Although the drug is not yet approved by the FDA, current clinical trials are open to new patients. And, the drug is being tested, with good results, on other cancers, such as multiple myeloma and B-cell lymphoma."
Early clinical trials show that the drug shrank the tumors of one-third of the patients in the breast cancer study –– a strong result, according to the authors. The studies explain that the drug works by targeting the microtubules of cancer cells. Microtubules are the dynamic, rapidly growing and shortening protein filaments that help cells to divide and multiply."We discovered how the drug is taken up into the tumor cells," said Jordan. "We found out that it is metabolized by the cancer cells, inhibits the dynamics of cellular microtubules, and thus blocks the mitosis of the spindles in the cells, causing them to die."
The drug was previously considered too dangerous to use, because of its toxicity to non-cancer cells. However, the team was able to show that modifying the anticancer drug by adding an antibody caused the drug to target only cancer cells, greatly reducing its toxicity.
The new drug, when linked with the breast cancer-targeting antibody, is named trastuzumab-DM1. DM1 is a synthetic derivative of maytansine, a molecule found in an evergreen tree in the genera Maytenus, which grows on several continents.
For more information on clinical trials, co-author Ravi Chari, of the pharmaceutical company Immunogen Inc., in Cambridge, Mass., suggests that interested cancer patients consult the Immunogen, Inc. Web site: http://www.immunogen.com/wt/home/home.
"Sometimes people say that there is no progress in the fight against cancer," said Jordan. "But there is progress on many fronts. There are many smaller advances on specific cancers. Les Wilson and I have been collaborating for 32 years, and it is very exciting and satisfying to both of us that many cancer drugs that we've worked on that inhibit microtubule dynamics are becoming successful in the clinic and are helping people to live."
Lopus completed his Ph.D. in biotechnology at the Indian Institute of Technology in Bombay. The other first author, Emin Oroudjev, was a project scientist with the same research team at the time of the study. He received his Ph.D. from the Russian Academy of Science and now works in Santa Barbara at Bio SB.
Gail Gallessich | EurekAlert!
More genes are active in high-performance maize
19.01.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn
How plants see light
19.01.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau
On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.
We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
19.01.2018 | Materials Sciences
19.01.2018 | Health and Medicine
19.01.2018 | Physics and Astronomy